|
Factors associated with worst HRQoL
|
MCS beta (p value)
|
PCS beta (p value)
|
|---|
|
EA
|
|
Age
|
NS
|
− 0.0064 (0.010)
|
|
DAS28-ESR
|
NS
|
+ 0.18 (< 0.001)
|
|
Levels of studies
|
NA
|
+ 0.26 (0.0001)
|
|
DMARDs
|
NS
|
+ 0.42 (< 0.001)
|
|
Symptom duration
|
NS
|
+ 0.0011 (0.048)
|
|
Score MCS at baseline
|
NS
|
+ 0.013 (< 0.001)
|
|
Score PCS at baseline
|
−0.049 (0.022)
|
− 0.041 (< 0.001)
|
|
Early IBP
|
|
ASDAS-CRP
|
NA
|
− 0.028 (< 0.001)
|
|
Age
|
NA
|
− 0.0012 (0.024)
|
|
Peripheral arthritis
|
NS
|
− 0.025 (0.0078)
|
|
TNFi
|
NA
|
− 0.028 (0.013)
|
|
Score MCS at baseline
|
−0.0085 (< 0.0001)
|
+ 0.0018 (< 0.001)
|
|
Score PCS at baseline
|
+ 0.0018 (0.02)
|
− 0.0055 (< 0.001)
|
- In EA, oral corticosteroid, smoking status and erosions were analyzed for MCS but were not significant. Oral corticosteroid was analysed for PCS but were not significant. In early IBP, female gender, lower symptom duration, studies above high school, presence of enthesitis, no radiological or MRI sacroiliitis were analysed for PCS but were not significant. Intermediate or high level employment were not analysed for PCS and were not significant for MCS. Both analyses were adjusted on baseline HRQoL
- DAS28-ESR Disease Activity Score—erythrocyte sedimentation rate, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score—C reactive protein, MCS mental composite score, PCS physical composite score, TNFi tumor necrosis factor inhibitor, NA not analysed (p value > 0.20 in univariate analysis), NS not significant
